Advances in Dermatology Therapeutics: Key Insights from AAD 2025
Highlights include new data on roflumilast cream 0.15%, an investigational anti-OX40 ligand monoclonal antibody, and more.
At the 2025 American Academy of Dermatology (AAD) Annual Meeting, exciting advancements in dermatologic therapies were unveiled for a variety of skin conditions, including atopic dermatitis (AD), psoriasis, hidradenitis suppurativa, and prurigo nodularis. This year’s highlights include promising results from late-stage clinical trials with novel oral, topical, and systemic treatments—such as phosphodiesterase-4 inhibitor roflumilast cream 1% for refractory AD, OX40 inhibitor rocatinlimab for moderate-to-severe AD, and triple cytokine inhibitor bimekizumab for long-term plaque psoriasis control. In the slides above, Patient Care© Online breaks down the key clinical findings for primary care clinicians.
